Trailblazing Study Shows Early CGP Leads to Better Precision Treatments

Rhea-AI Summary

A comprehensive study by Illumina, Providence, and Microsoft Research demonstrates that a 523-gene comprehensive genomic profiling (CGP) panel significantly improves cancer treatment outcomes. The study, published in the Journal of Clinical Oncology - Oncology Practice, analyzed 3,216 patients with advanced cancers. Key findings show that 67% of tumors contained actionable mutations using CGP, compared to 33% with a 50-gene panel. Patients receiving precision therapy based on CGP results showed median survival of 25 months versus 17 months for those on chemotherapy alone. The panel identified actionable variations in 52% of patients, qualifying them for targeted or immune therapy.

Positive

• CGP panel identified actionable mutations in 67% of tumors vs 33% for smaller panels
• Patients receiving precision therapy showed 8-month longer median survival (25 vs 17 months)
• 52% of CGP-tested patients qualified for targeted or immune therapy
• Study demonstrated clear clinical benefit of comprehensive genomic testing

Negative

• 88% of patients had metastatic disease
• 40% of study participants entered hospice
• effectiveness for some cancer types

Insights

Medical Research Analyst

This groundbreaking study demonstrates significant clinical value of Illumina's comprehensive genomic profiling (CGP) technology. The 523-gene panel showed remarkable efficacy, identifying actionable mutations in 67% of cases, compared to just 33% with traditional 50-gene panels. The impact on patient outcomes is substantial, with median survival increasing by 8 months for patients receiving precision therapies identified through CGP.

The collaboration with Providence and Microsoft Research adds credibility to the findings, while the large sample size of 3,216 patients provides robust statistical significance. The streamlined pathologist-initiated testing protocol and integration of AI for interpretation represents a scalable model for clinical implementation. The ongoing five-year study with 10,000+ patients suggests potential for even broader market adoption and clinical impact.

This positions Illumina strongly in the growing precision oncology market, with clear differentiation from competitors offering smaller panels. The successful clinical validation could drive increased adoption in healthcare systems and potentially influence insurance coverage policies.

NORTHAMPTON, MA / ACCESSWIRE / November 22, 2024 / Illumina
A 523-gene oncology panel identifies actionable tumor variations and improves outcomes

Originally published on Illumina News Center

A large, multiyear study conducted by Illumina, Providence, and Microsoft Research has shown that a comprehensive genomic profiling (CGP) panel, which can assess more than 500 genetic variations in tumors, is a powerful tool to direct patients to the most advanced precision therapies that improve overall survival. The study was published in the Journal of Clinical Oncology - Oncology Practice and will be presented at the Association for Molecular Pathology (AMP) 2024 meeting in Vancouver, British Columbia.

"With the comprehensive panel, we found that about half of our patients had at least one high-tier, actionable alteration, qualifying them for a precision therapy," says Brian Piening, PhD, director of Clinical Genomics at Providence, research faculty at the Earle A. Chiles Research Institute, and senior author on the paper. "Also, over half of our patients had a biomarker that would qualify them for a clinical trial. These are pretty striking results."

The evolution of genetic testing
Cancers are genetic diseases, in which genomic and chromosomal variations drive rampant cell growth. Over the past 30 years, clinicians have adopted increasingly sophisticated tests to identify these alterations and, when supported by evidence, refer patients to more effective therapies.

Early efforts were encouraging, but lacked breadth, often sequencing 50 or fewer genes and missing important tumor information. CGP provides a broader view of the diagnostic, prognostic, and predictive genetic variants underlying a patient's cancer.

Knowing a tumor's genomic blueprint can guide precision treatment. In many cases, if a mutated enzyme is causing uncontrolled cell growth, a targeted therapy can slow it down or stop it entirely. Immunotherapies harness a patient's own immune system to recognize and destroy tumors. These and other emerging treatments can dramatically improve patient outcomes-but first, clinicians must understand the genetic anomalies driving their tumors.

Streamlining protocol for CGP
The joint paper details the first two years of a five-year study to assess ProvSeq, a 523-gene panel used to test 3216 patients with advanced cancers (Stage III or IV). The team wanted to know if this comprehensive approach would identify more actionable anomalies than smaller genomic panels, and whether use of advanced therapies targeting those anomalies prolonged patient survival.

To remove insurance reimbursement from the equation, the researchers provided these tests at no cost. They also refined how CGP was ordered, to deliver the results faster and better influence care.

"We instituted a protocol where the test would be initiated when a pathologist diagnosed advanced cancer," Piening says. "Normally, oncologists ordered these, but we felt shifting it to pathologists would streamline the process. Having pathologists order CGP up front really brings it to the top of the list."

Using an approach developed by Microsoft Research collaborators and based on natural language processing, Providence clinical researchers were able to quickly and efficiently parse large sets of publications, clinical trials, and electronic health records. These AI capabilities assisted Providence researchers with genomics interpretation and clinical trial matching in the molecular tumor boards.

Robust results
The team ran simulations to compare ProvSeq's performance against that of a 50-gene panel on the same data. Unsurprisingly, the smaller panel failed to detect many actionable biomarkers.

The most common tumors found were lung, colon, breast and prostate. Around 88% of patients had metastatic disease, and 40% entered hospice. The CGP panel found that 67% of the tumors contained actionable mutations, compared to 33% for the small panel.

In addition, 52% of the CGP-tested patients received a targeted or immune therapy, dramatically improving overall survival. Median survival was 25 months for patients who received a precision therapy, compared to 17 months for those who received chemotherapy alone.

These raw statistics had real-world consequences. Because CGP identified actionable mutations in people with serious and possibly deadly tumors, those patients received the most precise treatments.

"A number of the participants had quite advanced, aggressive cancers," Piening says. "One patient was in hospice, and we found a highly targetable biomarker. The patient soon received the precision therapy and the response was remarkable. In a short time, they came off hospice and went back to work."

The research continues
In addition to the main paper, the team is also presenting two related posters at the AMP meeting. One showed that another genomic diagnostic could help determine whether ovarian cancer patients would respond to PARP inhibitors, which have shown some success against this challenging disease.

The team is also presenting on a subset of patients who had structural genomic variations called gene fusions. Some of these fusions were already well known but the scientists found several novel combinations, highlighting CGP's ability to detect unique genetic anomalies.

These findings are pieces of a much larger puzzle. The complete five-year study tested more than 10,000 patients, and researchers are waiting to learn more about their outcomes. This larger cohort could provide additional information about patients with relatively rare cancers.

The results are a positive step in CGP's clinical journey. Piening and his colleagues expect CGP-fueled patient outcomes to improve over time, as more targeted and immune therapies enter the clinic.

"We see new approvals all the time and that bodes well for the future," Piening says. "There's a lot of work to do, but those numbers will continue to climb. Ultimately, we'd like to be in a position where every patient has an available precision therapy option."

Photo: Brian Piening, PhD, director of Clinical Genomics at Providence | Photo courtesy of Providence

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.

Contact Info:
Spokesperson: Illumina
Website: https://www.3blmedia.com/profiles/illumina
Email: info@3blmedia.com

SOURCE: Illumina

View the original press release on accesswire.com

FAQ

What were the key findings of Illumina's (ILMN) CGP cancer study in 2024?

The study found that the 523-gene CGP panel identified actionable mutations in 67% of tumors, with patients receiving precision therapy showing 25-month median survival compared to 17 months for chemotherapy alone.

How many patients were included in Illumina's (ILMN) CGP cancer study?

The study included 3,216 patients with advanced cancers (Stage III or IV).

What percentage of patients received targeted therapy in Illumina's (ILMN) CGP study?

52% of patients tested with the CGP panel received targeted or immune therapy based on their results.

What types of cancers were most common in Illumina's (ILMN) 2024 CGP study?

The most common tumors found in the study were lung, colon, breast and prostate cancers.